EFTA01457561.pdf

11 May 2016 Pharmaceuticals GlaxoSmithKline Performance review charts 'Figure 6: Quarterly and annual Core EPS growth (CER, %) Figure 7: Pharma CER growth rates 10% 15 8% 9 9 10 - 7 5% 2% 5- I 2 ; 01 , 0% 0 4 • .3 .2 — 4 -1%2% -3% -3% -3% -316 .5 .4% -5% -to - 4% 4% - -g -11 -10% -15 - -12 -18 Ca N NCI CV IV e) el Ir O LT LS — N Cl 0 •15% • 3 94 NCVNNnelne100000 9R2g92289Rg99 )- Li. )- LL )- LL )- LL P.R999ggq9ggq9g999 Pan Oantb,(tint CanonSs Sane 0•4.0d0 ant aneenynil• I J 'Figure 8: Vaccines CER growth rates 'Figure 9: Consumer CER growth rates 20% t 14% 10% 10% 12% 10% l! 10% I 8% a j 1%016 i 0%31 " 0% i 8% 4% •10% I al 4% -20% I I -14% 41% 2% 18% O cc —1 3.41 1 116 en$ ;ilk 4% % 2i 4 5% .30% w 0% 2% I II -40% 2% 4% 3% .50% 4 34_ N n N N CI e) e) NI a R 0 0 VI -4% 6% 92M9ggq9Rgq9R299 CV CV Cl N Cl Cl ri O •LT R Lf W9R2R9RRS9RRS9 sew* Dome. bat anpony da Sown Accano ant Coroner 'Figure 10: Adyair CER growth rates 'Figure 1 t: New drug quarterly sales, £m 13% 1 250 9% 8% 193 4%5% 200 3% r 2% 2%2% 2% ar e " 150 •I F -2% 2% -1% -1% 3% 100 12953 50 1 -17% -15% 44% 15 I 4 8 -22% -18% 0 Cv N ea n f) t7 e) vr V • Le Yl 3013 4013 1014 2014 3014 4014 1015 P R RUM§ , AR§§RR§P SIN icayfrourneg 'DB's* Nana° Sane base* ark Ganasnaln Sacra D_. Bank Cams,. dos J Page 8 Deutsche Bank AG/London CONFIDENTIAL — PURSUANT TO FED. R CRIM. P. 6(e) DB-SDNY-0117158 CONFIDENTIAL SDNY_GM_00283342 EFTA01457561